Information Provided By: 
Fly News Breaks for July 23, 2019
KRTX
Jul 23, 2019 | 06:38 EDT
Citi analyst Mohit Bansal started Karuna Therapeutics with a Buy rating and $28 price target. If successful, the company's xanomeline would offer a new mechanism of action versus current antipsychotics, and would be the first treatment targeting negative and cognitive symptoms, Bansal tells investors in a research note. He believes the Phase 2 schizophrenia data by year-end 2019 "will further de-risk the program" and sees the opportunity in that setting reaching $2B in sales.
News For KRTX From the Last 2 Days
KRTX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
